Search

everythinglearnresearchcommunity

for

Search:↓

Hirsutism is mainly caused by high androgen levels or sensitivity, with PCOS being the most common cause.

Combining letrozole with metformin is the most effective treatment for inducing pregnancy in women with PCOS.

The document concludes that managing skin conditions during pregnancy is important and requires specialized care.

The document concludes that non-binary individuals need compassionate support and recognition in healthcare, without being pathologized.

Hair ages due to genetics and environmental factors, leading to graying and thinning, with treatments available for some conditions.

Testosterone replacement may help some postmenopausal women with symptoms like fatigue and low libido, but more research is needed to fully understand its effects.

The document concludes that early recognition and treatment of PCOS in adolescents is crucial for managing symptoms and long-term health risks.

Excessive hair growth in women often has no known cause and is not linked to race or other hormonal symptoms.

Non-binary transgender individuals need personalized hormonal treatments for better well-being and quality of life.

Hair problems are common and distressing for women, but increasing knowledge of treatments offers hope.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

The document concludes that managing hirsutism involves identifying the cause, using a scoring system for severity, combining cosmetic and medical treatments, encouraging weight loss, and providing psychological support, while noting the need for more research on drug treatments.

The document concludes that menopause should be seen as a natural part of aging and managed with personalized care and informed choices.

The document says that understanding the causes of PCOS is important for treatment, especially in distinguishing the syndrome from just having cystic ovaries, and that losing weight is key for obese women with PCOS.

Birth control pills combined with bicalutamide are more effective at reducing excessive hair growth in women with PCOS than birth control pills alone.

Women's ovarian hormones and adrenal androgens change throughout life, affecting hair loss and health.

The document concludes that health care providers should offer culturally competent care and more research is needed to improve health outcomes for transgender individuals.

The cause of atypical Cushing's syndrome in dogs, possibly linked to sex hormones, is not yet proven.

Treatments for common hair loss include minoxidil, finasteride, and hair transplantation.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.

Unwanted facial hair significantly impacts over 40% of women's psychological and social well-being, and various treatment options are available.

The document concludes that Rabson-Mendenhall syndrome requires novel treatments for insulin resistance and emphasizes the importance of dental care in affected patients.

Hyperadrenocorticism in ferrets is linked to neutering and indoor housing, and is best treated with surgery and a deslorelin implant.

Hair ages due to various factors and treatments like minoxidil and finasteride can help, but more research and better public awareness are needed.

Adalimumab is the most effective treatment for severe hidradenitis suppurativa, but more research is needed to improve treatment options.

Reproductive hormones play a crucial role in breast cancer development and treatment challenges.

Gender identity can be more diverse than just male or female.

Eating disorders can cause various hair problems, and while hair loss in these disorders is linked to metabolic syndrome, treatment focuses on specific medications and lifestyle changes for the syndrome.

The guidelines recommend informed consent for gender-affirming treatments and stress the importance of personalized, culturally sensitive care for transgender individuals.

Finasteride and minoxidil are effective for hair loss, but continued research is needed for better treatments.